Sinusitis Pipeline Summary

DelveInsight’s, “Sinusitis - Pipeline Insight, 2026” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Sinusitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Sinusitis: Understanding

Sinusitis: Overview

Sinusitis, more accurately termed rhinosinusitis, is an inflammatory disorder involving the mucosa of the nasal cavity and one or more paranasal sinuses. It may be classified according to duration as acute, subacute, or chronic, with chronic rhinosinusitis (CRS) generally defined by symptoms persisting for 12 weeks or longer. CRS is further divided into chronic rhinosinusitis with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP). Unlike acute disease, CRS is primarily regarded as a chronic inflammatory condition rather than simply an infection.

Common signs and symptoms include nasal congestion or obstruction, nasal discharge or postnasal drip, facial pain or pressure, and reduced or lost sense of smell. Patients may also experience headache, facial tenderness, cough, fatigue, halitosis, tooth discomfort and, particularly in acute disease, fever or malaise. Symptoms can vary according to disease phenotype and severity, with nasal polyps, asthma and allergic disease frequently occurring as associated conditions. Persistent symptoms can substantially affect sleep, daily functioning and health-related quality of life.

The causes and underlying mechanisms are multifactorial, involving infection, mucosal inflammation, impaired sinus drainage, allergy, anatomical abnormalities and environmental factors. Acute rhinosinusitis commonly follows a viral upper-respiratory infection, while a small proportion progresses to bacterial infection; chronic disease involves more complex epithelial and immune dysregulation. Obstruction of the sinus ostia and osteomeatal complex can impair mucus clearance, leading to mucus retention, altered local conditions and persistent inflammation. Allergic rhinitis, smoking, dental disease, asthma, immune disorders and certain anatomical variations can increase susceptibility.

Diagnosis is primarily based on clinical history and examination, with chronic rhinosinusitis requiring objective evidence of sinonasal inflammation through anterior rhinoscopy, nasal endoscopy or CT when appropriate. Treatment depends on disease type and severity and generally begins with conservative measures such as saline nasal irrigation and topical intranasal corticosteroids; antibiotics may be used when bacterial infection is suspected rather than routinely for inflammatory CRS. Persistent or severe disease may require systemic corticosteroids in selected cases, endoscopic sinus surgery, and for appropriately selected severe CRSwNP patients, targeted biologic therapies.

"Sinusitis- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Sinusitis pipeline landscape is provided which includes the disease overview and Sinusitis treatment guidelines. The assessment part of the report embraces, in depth Sinusitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sinusitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Sinusitis R&D. The therapies under development are focused on novel approaches to treat/improve Sinusitis.

Sinusitis Emerging Drugs Chapters

This segment of the Sinusitis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sinusitis Emerging Drugs

GR1802: Genrix (Shanghai) Biopharmaceutical Co., Ltd.

GR1802 is an investigational humanized monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4R?), developed by Genrix (Shanghai) Biopharmaceutical Co., Ltd. for inflammatory diseases including chronic rhinosinusitis with nasal polyps (CRSwNP). By blocking IL-4R? signaling, GR1802 is designed to inhibit Type 2 inflammatory pathways, which play an important role in the pathogenesis of CRSwNP. Clinical studies have reported improvements in nasal polyp score, nasal congestion, total nasal symptoms, SNOT-22 and Lund-Mackay scores in patients with uncontrolled CRSwNP. GR1802 is currently being evaluated in a Phase III trial in adults with severe CRSwNP, administered subcutaneously every two weeks, with the study assessing efficacy, safety and immunogenicity.

HTMC0658: Shanghai Huilun Pharmaceutical

HTMC0658 (also known as YD-0293) is an investigational small-molecule DPP-1 (dipeptidyl peptidase-1/cathepsin C) inhibitor being developed by Shanghai Yidian Pharmaceutical Technology Development Co., Ltd., a subsidiary of Shanghai Huilun Pharmaceutical for chronic rhinosinusitis without nasal polyps (CRSsNP). The rationale is to target neutrophil-related inflammation, with DPP-1 inhibition potentially reducing inflammatory activity associated with neutrophil-derived enzymes. HTMC0658 is currently being evaluated in a Phase IIa clinical trial, in which it is administered orally once daily for 12 weeks alongside mometasone furoate nasal spray. The trial is assessing changes in sinus CT findings (Lund-MacKay score), symptoms and quality of life, including SNOT-22, nasal congestion and rhinosinusitis severity, supporting its development as a potential disease-modifying treatment for CRSsNP.

VVN432: VivaVision Biotech

VVN432 is an investigational nasal spray being developed by VivaVision Biotech, Inc. for chronic rhinosinusitis (CRS). The clinical program is evaluating 0.5% and 1% VVN432 nasal spray, administered intranasally, for safety, tolerability, pharmacokinetics/pharmacodynamics, and preliminary efficacy. The Phase Ib portion specifically enrolls patients with chronic rhinosinusitis, with or without nasal polyps, and assesses measures including nasal congestion and total symptom scores. VVN432 is currently in Phase I development.

Further product details are provided in the report……..

Sinusitis: Therapeutic Assessment

This segment of the report provides insights about the different Sinusitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Sinusitis
• There are approx. 18+ key companies which are developing the therapies for Sinusitis. The companies which have their Sinusitis drug candidates in the most advanced stage, i.e. Phase III include, Genrix (Shanghai) Biopharmaceutical Co., Ltd.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Sinusitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sinusitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Sinusitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sinusitis drugs.

Sinusitis Report Insights

• Sinusitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sinusitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Sinusitis drugs?
• How many Sinusitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Sinusitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Sinusitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sinusitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Genrix (Shanghai) Biopharmaceutical Co., Ltd.
• Shanghai Huilun Pharmaceutical
• VIAL
• Lyra Therapeutics
• GeneOne Life Science
• Chia Tai Tianqing Pharmaceutical Technology Development
• VivaVision Biotech
• Qyuns Therapeutics
• Bambusa Therapeutics
• Sanofi
• KeyMed Biosciences
• Lanier Biotherapeutics

Key Products

• GR1802
• HTMC0658
• VIAL IL13 TSLP
• LYR-210
• GLS-1200
• TQC2731
• VVN432
• QX008N
• BBT002
• Lunsekimig
• CM-512
• LNR 125.38